Ran Zhu

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor

F. Liu, Ting-wei Liu, Ran Zhu, 2022, Frontiers in Pharmacology.

Sphingosine Kinase 2 Is Required for Modulation of Lymphocyte Traffic by FTY720*

V. Engelhard, K. Ley, K. Tung, 2005, Journal of Biological Chemistry.

N6-ethyl-2-alkynyl NECAs, selective human A3 adenosine receptor agonists.

J. Linden, T. Macdonald, Ran Zhu, 2006, Bioorganic & medicinal chemistry letters.

Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist.

T. Macdonald, K. Lynch, A. Snyder, 2007, Journal of medicinal chemistry.

Characterization of a Sphingosine 1-Phosphate Receptor Antagonist Prodrug

Thomas P Mathews, T. Macdonald, K. Lynch, 2008, Journal of Pharmacology and Experimental Therapeutics.

Pharmacokinetics, tissue distribution and excretion of a recombinant fusion protein 125I-rhTNT-IL2

You-jiu Zhang, Yuejin Chen, Yu-jie Xu, 2007 .

Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system.

T. Macdonald, F. Foss, Qin Sun, 2007, Bioorganic & medicinal chemistry letters.

In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity.

T. Macdonald, F. Foss, Qin Sun, 2008, Chemical research in toxicology.

Pharmacokinetic and Pharmacodynamic Characterization of a Sphingosine 1-phosphate Receptor Antagonist Prodrug

Thomas P Mathews, T. Macdonald, K. Lynch, 2011 .